Immunometabolic profiling of patients with multiple sclerosis identifies new biomarkers to predict disease activity during treatment with interferon beta-1a

Immunometabolic profiling of patients with multiple sclerosis identifies new biomarkers to predict disease activity during treatment with interferon beta-1a

Copyright © 2017 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 183(2017) vom: 15. Okt., Seite 249-253
1. Verfasser: Lanzillo, Roberta (VerfasserIn)
Weitere Verfasser: Carbone, Fortunata, Quarantelli, Mario, Bruzzese, Dario, Carotenuto, Antonio, De Rosa, Veronica, Colamatteo, Alessandra, Micillo, Teresa, De Luca Picione, Carla, Saccà, Francesco, De Rosa, Anna, Moccia, Marcello, Brescia Morra, Vincenzo, Matarese, Giuseppe
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2017
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Autoimmunity IFN-beta-1a IL-6 Leptin Adjuvants, Immunologic Biomarkers Interferon beta-1a XRO4566Q4R
Beschreibung
Zusammenfassung:Copyright © 2017 Elsevier Inc. All rights reserved.
Reliable immunologic biomarkers able to monitor disease course during multiple sclerosis (MS) are still missing. We aimed at identifying possible immunometabolic biomarkers able to predict the clinical outcome in MS patients during treatment with interferon (IFN)-beta-1a. We measured in 45 relapsing-remitting (RR) MS patients, blood circulating levels of several immunometabolic markers, at enrolment, and correlated their levels to disease activity and progression over time. Higher levels of interleukin (IL)-6, soluble-CD40-ligand (sCD40L) and leptin at baseline associated with a higher relapse rate and a greater risk of experiencing at least one relapse in the following year. Higher values of soluble tumor necrosis factor receptor (sTNF-R) and leptin at baseline were predictive of a higher number of lesions in the following one-year of follow up. In conclusion, our data suggest that an immunometabolic profiling measuring IL-6, sCD40L, leptin and sTNF-R at baseline, could represent a useful tool to predict disease course in RRMS patients during treatment with IFN-beta-1a
Beschreibung:Date Completed 13.12.2017
Date Revised 06.02.2018
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2017.08.011